{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:10:11Z","timestamp":1787069411314,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":189,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319524788","type":"print"},{"value":"9783319524795","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-52479-5_2","type":"book-chapter","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T07:39:21Z","timestamp":1490686761000},"page":"21-48","source":"Crossref","is-referenced-by-count":26,"title":["Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Ren\u00e3 A. S.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"issue":"4","key":"2_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00002093-200110000-00002","volume":"15","author":"LE Hebert","year":"2001","unstructured":"Hebert LE, Beckett LA, Scherr PA, Evans DA (2001) Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15(4):169\u2013173","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"2_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9(1):63\u201375.e62. doi: 10.1016\/j.jalz.2012.11.007","journal-title":"Alzheimers Dement"},{"key":"2_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.18773\/austprescr.2015.071","volume":"38","author":"D Kitching","year":"2015","unstructured":"Kitching D (2015) Depression in dementia. Aust Prescr 38:209\u2013211","journal-title":"Aust Prescr"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biopsych.2013.08.020","volume":"75","author":"PS Murray","year":"2014","unstructured":"Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA (2014) Psychosis in Alzheimer\u2019s disease. Biol Psychiatry 75:542\u2013552","journal-title":"Biol Psychiatry"},{"issue":"6","key":"2_CR5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jalz.2015.05.016","volume":"11","author":"M Baumgart","year":"2015","unstructured":"Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11(6):718\u2013726. doi: 10.1016\/j.jalz.2015.05.016","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","volume":"88","author":"C Reitz","year":"2014","unstructured":"Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88(4):640\u2013651. doi: 10.1016\/j.bcp.2013.12.024","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.21623","volume":"66","author":"RJ Bateman","year":"2009","unstructured":"Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC et al (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66(1):48\u201354. doi: 10.1002\/ana.21623","journal-title":"Ann Neurol"},{"issue":"3 Suppl","key":"2_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3233\/JAD-2006-9S338","volume":"9","author":"A Goate","year":"2006","unstructured":"Goate A (2006) Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer\u2019s disease. J Alzheimers Dis 9(3 Suppl):341\u2013347","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"2_CR9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm1096-1146","volume":"2","author":"CA Lemere","year":"1996","unstructured":"Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC et al (1996) The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2(10):1146\u20131150","journal-title":"Nat Med"},{"issue":"5226","key":"2_CR10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH et al (1995) Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science 269(5226):973\u2013977","journal-title":"Science"},{"issue":"6543","key":"2_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"EI Rogaev","year":"1995","unstructured":"Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y et al (1995) Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature 376(6543):775\u2013778. doi: 10.1038\/376775a0","journal-title":"Nature"},{"issue":"8","key":"2_CR12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2(8):864\u2013870","journal-title":"Nat Med"},{"issue":"6534","key":"2_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 375(6534):754\u2013760. doi: 10.1038\/375754a0","journal-title":"Nature"},{"issue":"1","key":"2_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng1934","volume":"39","author":"L Bertram","year":"2007","unstructured":"Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39(1):17\u201323. doi: 10.1038\/ng1934","journal-title":"Nat Genet"},{"issue":"5123","key":"2_CR15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261(5123):921\u2013923","journal-title":"Science"},{"issue":"16","key":"2_CR16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16):1349\u20131356","journal-title":"JAMA"},{"key":"2_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/CIA.S105769","volume":"11","author":"M Giri","year":"2016","unstructured":"Giri M, Zhang M, Lu Y (2016) Genes associated with Alzheimer\u2019s disease: an overview and current status. Clin Interv Aging 11:665\u2013681. doi: 10.2147\/CIA.S105769","journal-title":"Clin Interv Aging"},{"issue":"2","key":"2_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-016-0011-3","volume":"32","author":"L Shen","year":"2016","unstructured":"Shen L, Jia J (2016) An overview of Genome-Wide Association Studies in Alzheimer\u2019s disease. Neurosci Bull 32(2):183\u2013190. doi: 10.1007\/s12264-016-0011-3","journal-title":"Neurosci Bull"},{"issue":"4","key":"2_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D et al (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol 38(4):643\u2013648. doi: 10.1002\/ana.410380413","journal-title":"Ann Neurol"},{"issue":"4","key":"2_CR20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4):652\u2013656","journal-title":"Neurology"},{"issue":"4","key":"2_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15622970310029912","volume":"4","author":"N Andreasen","year":"2003","unstructured":"Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer\u2019s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4(4):147\u2013155","journal-title":"World J Biol Psychiatry"},{"issue":"9","key":"2_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","volume":"68","author":"AM Fagan","year":"2011","unstructured":"Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ et al (2011) Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68(9):1137\u20131144. doi: 10.1001\/archneurol.2011.105","journal-title":"Arch Neurol"},{"issue":"3","key":"2_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382\u2013389. doi: 10.1001\/archneurol.2008.596","journal-title":"Arch Neurol"},{"issue":"5","key":"2_CR24","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","volume":"61","author":"M Vandermeeren","year":"1993","unstructured":"Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ et al (1993) Detection of tau proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61(5):1828\u20131834","journal-title":"J Neurochem"},{"issue":"7","key":"2_CR25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer\u2019s disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"3","key":"2_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):263\u2013269. doi: 10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/2211068214559979","volume":"20","author":"C Schaffer","year":"2015","unstructured":"Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J et al (2015) Biomarkers in the diagnosis and prognosis of Alzheimer\u2019s disease. J Lab Autom 20(5):589\u2013600. doi: 10.1177\/2211068214559979","journal-title":"J Lab Autom"},{"issue":"9","key":"2_CR28","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","volume":"56","author":"DS Knopman","year":"2001","unstructured":"Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N et al (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56(9):1143\u20131153","journal-title":"Neurology"},{"issue":"3","key":"2_CR29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/geront\/43.3.295","volume":"43","author":"FJ Kier","year":"2003","unstructured":"Kier FJ, Molinari V (2003) \"Do-it-yourself\" dementia testing: issues regarding an Alzheimer\u2019s home screening test. Gerontologist 43(3):295\u2013301","journal-title":"Gerontologist"},{"issue":"4","key":"2_CR30","first-page":"286","volume":"13","author":"DS Knopman","year":"2000","unstructured":"Knopman DS, Knudson D, Yoes ME, Weiss DJ (2000) Development and standardization of a new telephonic cognitive screening test: the Minnesota Cognitive Acuity Screen (MCAS). Neuropsychiatry Neuropsychol Behav Neurol 13(4):286\u2013296","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"6","key":"2_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/GIM.0b013e31821d69b8","volume":"13","author":"JS Goldman","year":"2011","unstructured":"Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M et al (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13(6):597\u2013605. doi: 10.1097\/GIM.0b013e31821d69b8","journal-title":"Genet Med"},{"issue":"4","key":"2_CR32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4):351\u2013357","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69(1):181\u2013192. doi: 10.1002\/ana.22248","journal-title":"Ann Neurol"},{"key":"2_CR34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/YCO.0b013e32834bb9d4","volume":"24","author":"D Enache","year":"2011","unstructured":"Enache D, Winblad B, Aarsland D (2011) Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry 24:461\u2013472","journal-title":"Curr Opin Psychiatry"},{"key":"2_CR35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/gps.2631","volume":"26","author":"K Engedal","year":"2011","unstructured":"Engedal K, Barca ML, Laks J, Selbaek G (2011) Depression in Alzheimer\u2019s disease: specificity of depressive symptoms using three different clinical criteria. Int J Geriatr Psychiatry 26:944\u2013951","journal-title":"Int J Geriatr Psychiatry"},{"key":"2_CR36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/gps.2697","volume":"27","author":"DR Royall","year":"2012","unstructured":"Royall DR, Palmer R, Chiodo LK, Polk MJ (2012) Depressive symptoms predict longitudinal change in executive control but not memory. Int J Geriatr Psychiatry 27:89\u201396","journal-title":"Int J Geriatr Psychiatry"},{"key":"2_CR37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13825585.2013.795514","volume":"21","author":"NC Rushing","year":"2014","unstructured":"Rushing NC, Sachs-Ericsson N, Steffens DC (2014) Neuropsychological indicators of preclinical Alzheimer\u2019s disease among depressed older adults. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 21:99\u2013128","journal-title":"Neuropsychol Dev Cogn B Aging Neuropsychol Cogn"},{"key":"2_CR38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"QF Zhao","year":"2016","unstructured":"Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L et al (2016) The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. J Affect Disord 190:264\u2013271","journal-title":"J Affect Disord"},{"key":"2_CR39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jgs.12600","volume":"62","author":"LB Zahodne","year":"2014","unstructured":"Zahodne LB, Stern Y, Manly JJ (2014) Depressive symptoms precede memory decline, but not vice versa, in non-demented older adults. J Am Geriatr Soc 62:130\u2013134","journal-title":"J Am Geriatr Soc"},{"key":"2_CR40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4088\/JCP.08m04724gry","volume":"71","author":"LL Boyle","year":"2010","unstructured":"Boyle LL, Porsteinsson AP, Cui X, King DA, Lyness JM (2010) Depression predicts cognitive disorders in older primary care patients. J Clin Psychiatry 71:74\u201379","journal-title":"J Clin Psychiatry"},{"key":"2_CR41","doi-asserted-by":"crossref","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d. Clin Anat 8:429\u2013431","DOI":"10.1002\/ca.980080612"},{"key":"2_CR42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","volume":"23","author":"M Steinberg","year":"2008","unstructured":"Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC et al (2008) Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23:170\u2013177","journal-title":"Int J Geriatr Psychiatry"},{"key":"2_CR43","volume-title":"Dementia and milder cognitive syndromes. The American psychiatric publishing textbook of geriatric psychiatry","author":"CG Lyketsos","year":"2009","unstructured":"Lyketsos CG (2009) Dementia and milder cognitive syndromes. The American psychiatric publishing textbook of geriatric psychiatry, 4th edn. American Psychiatric Publishing, Virginia","edition":"4"},{"key":"2_CR44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jagp.2013.01.051","volume":"21","author":"J Vilalta-Franch","year":"2013","unstructured":"Vilalta-Franch J, L\u00f3pez-Pousa S, Calv\u00f3-Perxas L, Garre-Olmo J (2013) Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry 21:1135\u20131143","journal-title":"Am J Geriatr Psychiatry"},{"key":"2_CR45","doi-asserted-by":"publisher","unstructured":"Shah C, DeMichele-Sweet MA, Sweet RA (2016) Genetics of psychosis of Alzheimer disease. Am J Med Genet B Neuropsychiatr Genet doi: 10.1002\/ajmg.b.32413 . [Epub ahead of print]","DOI":"10.1002\/ajmg.b.32413"},{"issue":"3","key":"2_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/alzrt185","volume":"5","author":"VB Gupta","year":"2013","unstructured":"Gupta VB, Sundaram R, Martins RN (2013) Multiplex biomarkers in blood. Alzheimers Res Ther 5(3):31. doi: 10.1186\/alzrt185","journal-title":"Alzheimers Res Ther"},{"issue":"24","key":"2_CR47","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24):2197\u20132204. doi: 10.1212\/01.wnl.0000271090.28148.24","journal-title":"Neurology"},{"issue":"3","key":"2_CR48","doi-asserted-by":"publisher","first-page":"622 e621","DOI":"10.1016\/j.neurobiolaging.2011.02.018","volume":"33","author":"GA Jicha","year":"2012","unstructured":"Jicha GA, Abner EL, Schmitt FA, Kryscio RJ, Riley KP, Cooper GE et al (2012) Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33(3):622 e621\u2013622 e616. doi: 10.1016\/j.neurobiolaging.2011.02.018","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2_CR49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1750-3639.2008.00244.x","volume":"20","author":"PT Nelson","year":"2010","unstructured":"Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD et al (2010) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 20(1):66\u201379. doi: 10.1111\/j.1750-3639.2008.00244.x","journal-title":"Brain Pathol"},{"issue":"8","key":"2_CR50","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/01.wnl.0000180958.22678.91","volume":"65","author":"CR Jack Jr","year":"2005","unstructured":"Jack CR Jr, Shiung MM, Weigand SD, O\u2019Brien PC, Gunter JL, Boeve BF et al (2005) Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65(8):1227\u20131231. doi: 10.1212\/01.wnl.0000180958.22678.91","journal-title":"Neurology"},{"key":"2_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fnagi.2016.00139","volume":"8","author":"MJ Knight","year":"2016","unstructured":"Knight MJ, McCann B, Kauppinen RA, Coulthard EJ (2016) Magnetic resonance imaging to detect early molecular and cellular changes in Alzheimer\u2019s disease. Front Aging Neurosci 8:139. doi: 10.3389\/fnagi.2016.00139","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"2_CR52","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1212\/01.WNL.0000160089.43264.1A","volume":"64","author":"TR Stoub","year":"2005","unstructured":"Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA et al (2005) MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 64(9):1520\u20131524. doi: 10.1212\/01.WNL.0000160089.43264.1A","journal-title":"Neurology"},{"issue":"7","key":"2_CR53","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.neurobiolaging.2008.08.003","volume":"31","author":"TR Stoub","year":"2010","unstructured":"Stoub TR, Rogalski EJ, Leurgans S, Bennett DA, deToledo-Morrell L (2010) Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function. Neurobiol Aging 31(7):1089\u20131098. doi: 10.1016\/j.neurobiolaging.2008.08.003","journal-title":"Neurobiol Aging"},{"key":"2_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","volume":"1180","author":"HD Soares","year":"2009","unstructured":"Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M (2009) Identifying early markers of Alzheimer\u2019s disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180:56\u201367. doi: 10.1111\/j.1749-6632.2009.05066.x","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2_CR55","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/ana.20799","volume":"59","author":"W Jagust","year":"2006","unstructured":"Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M (2006) Brain imaging evidence of preclinical Alzheimer\u2019s disease in normal aging. Ann Neurol 59(4):673\u2013681. doi: 10.1002\/ana.20799","journal-title":"Ann Neurol"},{"issue":"3","key":"2_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","volume":"6","author":"WJ Jagust","year":"2010","unstructured":"Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA et al (2010) The Alzheimer\u2019s disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 6(3):221\u2013229. doi: 10.1016\/j.jalz.2010.03.003","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2_CR57","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.neuroimage.2008.12.072","volume":"45","author":"JB Langbaum","year":"2009","unstructured":"Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS et al (2009) Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Neuroimage 45(4):1107\u20131116. doi: 10.1016\/j.neuroimage.2008.12.072","journal-title":"Neuroimage"},{"key":"2_CR58","doi-asserted-by":"publisher","unstructured":"Mosconi L (2013) Glucose metabolism in normal aging and Alzheimer\u2019s disease: methodological and physiological considerations for PET studies. Clin Transl Imaging 1(4). doi: 10.1007\/s40336-013-0026-y","DOI":"10.1007\/s40336-013-0026-y"},{"issue":"10","key":"2_CR59","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.3390\/ijms131012629","volume":"13","author":"K Shah","year":"2012","unstructured":"Shah K, Desilva S, Abbruscato T (2012) The role of glucose transporters in brain disease: diabetes and Alzheimer\u2019s disease. Int J Mol Sci 13(10):12629\u201312655. doi: 10.3390\/ijms131012629","journal-title":"Int J Mol Sci"},{"key":"2_CR60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-394816-8.00002-7","volume":"64","author":"AD Cohen","year":"2012","unstructured":"Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD (2012) Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol 64:27\u201381. doi: 10.1016\/B978-0-12-394816-8.00002-7","journal-title":"Adv Pharmacol"},{"issue":"2","key":"2_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/archneur.62.2.196","volume":"62","author":"CA Mathis","year":"2005","unstructured":"Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62(2):196\u2013200. doi: 10.1001\/archneur.62.2.196","journal-title":"Arch Neurol"},{"issue":"3","key":"2_CR62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228\u2013234. doi: 10.1016\/S1474-4422(06)70355-6","journal-title":"Lancet Neurol"},{"key":"2_CR63","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fnins.2015.00345","volume":"9","author":"K Blennow","year":"2015","unstructured":"Blennow K, Zetterberg H (2015) The past and the future of Alzheimer\u2019s disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci 9:345. doi: 10.3389\/fnins.2015.00345","journal-title":"Front Neurosci"},{"issue":"10","key":"2_CR64","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ et al (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry 68(10):903\u2013912. doi: 10.1016\/j.biopsych.2010.08.025","journal-title":"Biol Psychiatry"},{"issue":"1","key":"2_CR65","doi-asserted-by":"publisher","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","volume":"6","author":"RJ Perrin","year":"2011","unstructured":"Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE et al (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer\u2019s disease. PLoS One 6(1):e16032. doi: 10.1371\/journal.pone.0016032","journal-title":"PLoS One"},{"issue":"2","key":"2_CR66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2013.02.026","volume":"78","author":"C Cruchaga","year":"2013","unstructured":"Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM et al (2013) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer\u2019s disease. Neuron 78(2):256\u2013268. doi: 10.1016\/j.neuron.2013.02.026","journal-title":"Neuron"},{"issue":"10","key":"2_CR67","doi-asserted-by":"publisher","first-page":"e1004758","DOI":"10.1371\/journal.pgen.1004758","volume":"10","author":"JS Kauwe","year":"2014","unstructured":"Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL et al (2014) Genome-wide association study of CSF levels of 59 alzheimer\u2019s disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet 10(10):e1004758. doi: 10.1371\/journal.pgen.1004758","journal-title":"PLoS Genet"},{"issue":"4","key":"2_CR68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000245156","volume":"28","author":"KS Lee","year":"2009","unstructured":"Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH (2009) Peripheral cytokines and chemokines in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 28(4):281\u2013287. doi: 10.1159\/000245156","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"243","key":"2_CR69","doi-asserted-by":"publisher","first-page":"243ra286","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6(243):243ra286. doi: 10.1126\/scitranslmed.3009093","journal-title":"Sci Transl Med"},{"key":"2_CR70","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fneur.2015.00256","volume":"6","author":"D Galasko","year":"2015","unstructured":"Galasko D (2015) Expanding the repertoire of biomarkers for Alzheimer\u2019s disease: targeted and non-targeted approaches. Front Neurol 6:256. doi: 10.3389\/fneur.2015.00256","journal-title":"Front Neurol"},{"issue":"3","key":"2_CR71","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S et al (2013) CSF biomarker variability in the Alzheimer\u2019s Association quality control program. Alzheimers Dement 9(3):251\u2013261. doi: 10.1016\/j.jalz.2013.01.010","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2_CR72","doi-asserted-by":"publisher","first-page":"e100784","DOI":"10.1371\/journal.pone.0100784","volume":"9","author":"SJ Vos","year":"2014","unstructured":"Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I et al (2014) Variability of CSF Alzheimer\u2019s disease biomarkers: implications for clinical practice. PLoS One 9(6):e100784. doi: 10.1371\/journal.pone.0100784","journal-title":"PLoS One"},{"issue":"3","key":"2_CR73","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512\u2013519. doi: 10.1002\/ana.20730","journal-title":"Ann Neurol"},{"issue":"10","key":"2_CR74","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29(10):1456\u20131465. doi: 10.1016\/j.neurobiolaging.2007.03.029","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61(1):95\u2013102. doi: 10.1001\/archpsyc.61.1.95","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2_CR76","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-141986","volume":"45","author":"H Struyfs","year":"2015","unstructured":"Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C et al (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis 45(3):813\u2013822. doi: 10.3233\/JAD-141986","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2_CR77","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y et al (2009) Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8(7):619\u2013627. doi: 10.1016\/S1474-4422(09)70139-5","journal-title":"Lancet Neurol"},{"issue":"4","key":"2_CR78","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol 65(4):403\u2013413. doi: 10.1002\/ana.21610","journal-title":"Ann Neurol"},{"issue":"5","key":"2_CR79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF03256296","volume":"12","author":"A Lonneborg","year":"2008","unstructured":"Lonneborg A (2008) Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood. Mol Diagn Ther 12(5):307\u2013320","journal-title":"Mol Diagn Ther"},{"key":"2_CR80","doi-asserted-by":"publisher","first-page":"572495","DOI":"10.4061\/2011\/572495","volume":"2011","author":"S Patel","year":"2011","unstructured":"Patel S, Shah RJ, Coleman P, Sabbagh M (2011) Potential peripheral biomarkers for the diagnosis of Alzheimer\u2019s disease. Int J Alzheimers Dis 2011:572495. doi: 10.4061\/2011\/572495","journal-title":"Int J Alzheimers Dis"},{"issue":"3","key":"2_CR81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3233\/JAD-2001-3310","volume":"3","author":"SM De La Monte","year":"2001","unstructured":"De La Monte SM, Wands JR (2001) The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer\u2019s disease. J Alzheimers Dis 3(3):345\u2013353","journal-title":"J Alzheimers Dis"},{"key":"2_CR82","first-page":"d989","volume":"7","author":"SM Monte de la","year":"2002","unstructured":"de la Monte SM, Wands JR (2002) The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer\u2019s disease. Front Biosci 7:d989\u2013d996","journal-title":"Front Biosci"},{"issue":"4","key":"2_CR83","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jocn.2014.10.011","volume":"22","author":"L Ma","year":"2015","unstructured":"Ma L, Chen J, Wang R, Han Y, Zhang J, Dong W et al (2015) The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. J Clin Neurosci 22(4):649\u2013652. doi: 10.1016\/j.jocn.2014.10.011","journal-title":"J Clin Neurosci"},{"issue":"5","key":"2_CR84","first-page":"277","volume":"70","author":"J Kang","year":"2015","unstructured":"Kang J, Lu J, Zhang X (2015) Metabolomics-based promising candidate biomarkers and pathways in Alzheimer\u2019s disease. Pharmazie 70(5):277\u2013282","journal-title":"Pharmazie"},{"issue":"8","key":"2_CR85","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.bbadis.2013.06.014","volume":"1842","author":"E Trushina","year":"2014","unstructured":"Trushina E, Mielke MM (2014) Recent advances in the application of metabolomics to Alzheimer\u2019s disease. Biochim Biophys Acta 1842(8):1232\u20131239. doi: 10.1016\/j.bbadis.2013.06.014","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2_CR86","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s12264-012-1272-0","volume":"28","author":"XH Xu","year":"2012","unstructured":"Xu XH, Huang Y, Wang G, Chen SD (2012) Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer\u2019s disease. Neurosci Bull 28(5):641\u2013648. doi: 10.1007\/s12264-012-1272-0","journal-title":"Neurosci Bull"},{"key":"2_CR87","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fneur.2015.00236","volume":"6","author":"AL Baird","year":"2015","unstructured":"Baird AL, Westwood S, Lovestone S (2015) Blood-based proteomic biomarkers of Alzheimer\u2019s disease pathology. Front Neurol 6:236. doi: 10.3389\/fneur.2015.00236","journal-title":"Front Neurol"},{"key":"2_CR88","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/978-1-4939-2627-5_32","volume":"1303","author":"R Perneczky","year":"2016","unstructured":"Perneczky R, Guo LH (2016) Plasma proteomics biomarkers in Alzheimer\u2019s disease: latest advances and challenges. Methods Mol Biol 1303:521\u2013529. doi: 10.1007\/978-1-4939-2627-5_32","journal-title":"Methods Mol Biol"},{"key":"2_CR89","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/bmm-2015-0055","volume":"10","author":"FL Guest","year":"2016","unstructured":"Guest FL, Guest PC, Martins-de-Souza D (2016) The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine. Biomark Med 10:431\u2013443","journal-title":"Biomark Med"},{"issue":"11","key":"2_CR90","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K et al (2007) Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med 13(11):1359\u20131362. doi: 10.1038\/nm1653","journal-title":"Nat Med"},{"issue":"5","key":"2_CR91","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/acschemneuro.6b00042","volume":"7","author":"LF Clark","year":"2016","unstructured":"Clark LF, Kodadek T (2016) The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease. ACS Chem Nerosci 7(5):520\u2013527. doi: 10.1021\/acschemneuro.6b00042","journal-title":"ACS Chem Nerosci"},{"key":"2_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neurobiolaging.2015.10.021","volume":"38","author":"A Chen","year":"2016","unstructured":"Chen A, Oakley AE, Monteiro M, Tuomela K, Allan LM, Mukaetova-Ladinska EB et al (2016) Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging 38:56\u201367. doi: 10.1016\/j.neurobiolaging.2015.10.021","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2_CR93","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3988\/jcn.2008.4.2.84","volume":"4","author":"C Choi","year":"2008","unstructured":"Choi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J et al (2008) Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer\u2019s disease by color-coded bead technology. J Clin Neurol 4(2):84\u201388. doi: 10.3988\/jcn.2008.4.2.84","journal-title":"J Clin Neurol"},{"key":"2_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fneur.2015.00181","volume":"6","author":"C Delaby","year":"2015","unstructured":"Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J et al (2015) Central nervous system and peripheral inflammatory processes in Alzheimer\u2019s disease: biomarker profiling approach. Front Neurol 6:181. doi: 10.3389\/fneur.2015.00181","journal-title":"Front Neurol"},{"issue":"1","key":"2_CR95","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000330468","volume":"1","author":"T Hochstrasser","year":"2011","unstructured":"Hochstrasser T, Marksteiner J, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C (2011) Two blood monocytic biomarkers (CCL15 and p21) combined with the mini-mental state examination discriminate Alzheimer\u2019s disease patients from healthy subjects. Dement Geriatr Cogn Dis Extra 1(1):297\u2013309. doi: 10.1159\/000330468","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"8","key":"2_CR96","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.neurobiolaging.2005.03.006","volume":"26","author":"I Blasko","year":"2005","unstructured":"Blasko I, Kemmler G, Krampla W, Jungwirth S, Wichart I, Jellinger K et al (2005) Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging 26(8):1135\u20131143. doi: 10.1016\/j.neurobiolaging.2005.03.006","journal-title":"Neurobiol Aging"},{"issue":"5","key":"2_CR97","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/jcbfm.2011.179","volume":"32","author":"Y Tian","year":"2012","unstructured":"Tian Y, Stamova B, Jickling GC, Liu D, Ander BP, Bushnell C et al (2012) Effects of gender on gene expression in the blood of ischemic stroke patients. J Cereb Blood Flow Metab 32(5):780\u2013791. doi: 10.1038\/jcbfm.2011.179","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"2_CR98","doi-asserted-by":"publisher","first-page":"e70269","DOI":"10.1371\/journal.pone.0070269","volume":"8","author":"S Kim","year":"2013","unstructured":"Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L et al (2013) Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One 8(7):e70269. doi: 10.1371\/journal.pone.0070269","journal-title":"PLoS One"},{"issue":"11","key":"2_CR99","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","volume":"1","author":"NL Anderson","year":"2002","unstructured":"Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845\u2013867","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"2_CR100","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB et al (2015) Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement 11(6):600\u2013607.e1. doi: 10.1016\/j.jalz.2014.06.008","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2_CR101","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","volume":"128","author":"M Shi","year":"2014","unstructured":"Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C et al (2014) Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease. Acta Neuropathol 128(5):639\u2013650. doi: 10.1007\/s00401-014-1314-y","journal-title":"Acta Neuropathol"},{"key":"2_CR102","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jprot.2014.04.028","volume":"106","author":"D Chiasserini","year":"2014","unstructured":"Chiasserini D, van Weering JR, Piersma SR, Pham TV, Malekzadeh A, Teunissen CE et al (2014) Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J Proteomics 106:191\u2013204. doi: 10.1016\/j.jprot.2014.04.028","journal-title":"J Proteomics"},{"issue":"1","key":"2_CR103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00441-012-1428-2","volume":"352","author":"A Schneider","year":"2013","unstructured":"Schneider A, Simons M (2013) Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res 352(1):33\u201347. doi: 10.1007\/s00441-012-1428-2","journal-title":"Cell Tissue Res"},{"key":"2_CR104","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fncel.2015.00053","volume":"9","author":"S Garza-Manero","year":"2015","unstructured":"Garza-Manero S, Arias C, Bermudez-Rattoni F, Vaca L, Zepeda A (2015) Identification of age- and disease-related alterations in circulating miRNAs in a mouse model of Alzheimer\u2019s disease. Front Cell Neurosci 9:53. doi: 10.3389\/fncel.2015.00053","journal-title":"Front Cell Neurosci"},{"key":"2_CR105","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fneur.2015.00162","volume":"6","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Bhattacharjee S, Dua P, Alexandrov PN, Lukiw WJ (2015) microRNA-based biomarkers and the diagnosis of Alzheimer\u2019s disease. Front Neurol 6:162. doi: 10.3389\/fneur.2015.00162","journal-title":"Front Neurol"},{"issue":"2","key":"2_CR106","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","volume":"51","author":"A Olsson","year":"2005","unstructured":"Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B et al (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51(2):336\u2013345. doi: 10.1373\/clinchem.2004.039347","journal-title":"Clin Chem"},{"issue":"8","key":"2_CR107","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52(8):1555\u20131562","journal-title":"Neurology"},{"issue":"1","key":"2_CR108","first-page":"40","volume":"2","author":"G Biella","year":"2013","unstructured":"Biella G, Franceschi M, De Rino F, Davin A, Giacalone G, Brambilla P et al (2013) Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer\u2019s disease. Am J Neurodegener Dis 2(1):40\u201345","journal-title":"Am J Neurodegener Dis"},{"issue":"1","key":"2_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2006.07.009","volume":"409","author":"P Lewczuk","year":"2006","unstructured":"Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A et al (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409(1):1\u20134. doi: 10.1016\/j.neulet.2006.07.009","journal-title":"Neurosci Lett"},{"key":"2_CR110","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fneur.2015.00202","volume":"6","author":"M Del Campo","year":"2015","unstructured":"Del Campo M, Jongbloed W, Twaalfhoven HA, Veerhuis R, Blankenstein MA, Teunissen CE (2015) Facilitating the validation of novel protein biomarkers for dementia: an optimal workflow for the development of sandwich immunoassays. Front Neurol 6:202. doi: 10.3389\/fneur.2015.00202","journal-title":"Front Neurol"},{"issue":"5","key":"2_CR111","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1373\/clinchem.2006.081679","volume":"53","author":"TS Reijn","year":"2007","unstructured":"Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM (2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 53(5):859\u2013865. doi: 10.1373\/clinchem.2006.081679","journal-title":"Clin Chem"},{"issue":"2","key":"2_CR112","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JAD-2012-120082","volume":"31","author":"LS Wang","year":"2012","unstructured":"Wang LS, Leung YY, Chang SK, Leight S, Knapik-Czajka M, Baek Y et al (2012) Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. J Alzheimers Dis 31(2):439\u2013445. doi: 10.3233\/JAD-2012-120082","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2_CR113","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/mp.2013.40","volume":"19","author":"SC Burnham","year":"2014","unstructured":"Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J et al (2014) A blood-based predictor for neocortical Abeta burden in Alzheimer\u2019s disease: results from the AIBL study. Mol Psychiatry 19(4):519\u2013526. doi: 10.1038\/mp.2013.40","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2_CR114","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/WAD.0b013e31827b60d2","volume":"27","author":"LH Guo","year":"2013","unstructured":"Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R, Alzheimer\u2019s Disease Neuroimaging I (2013) Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord 27(4):337\u2013342. doi: 10.1097\/WAD.0b013e31827b60d2","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"2_CR115","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ymeth.2005.11.010","volume":"38","author":"MF Elshal","year":"2006","unstructured":"Elshal MF, McCoy JP (2006) Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38(4):317\u2013323. doi: 10.1016\/j.ymeth.2005.11.010","journal-title":"Methods"},{"issue":"4","key":"2_CR116","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ymeth.2012.03.023","volume":"56","author":"JH Kang","year":"2012","unstructured":"Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM (2012) Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer\u2019s disease. Methods 56(4):484\u2013493. doi: 10.1016\/j.ymeth.2012.03.023","journal-title":"Methods"},{"issue":"5","key":"2_CR117","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-011-0808-0","volume":"121","author":"LM Shaw","year":"2011","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121(5):597\u2013609. doi: 10.1007\/s00401-011-0808-0","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2_CR118","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/archneurol.2009.59","volume":"66","author":"EC Petrie","year":"2009","unstructured":"Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER et al (2009) Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 66(5):632\u2013637. doi: 10.1001\/archneurol.2009.59","journal-title":"Arch Neurol"},{"issue":"6","key":"2_CR119","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","volume":"119","author":"WT Hu","year":"2010","unstructured":"Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM et al (2010) Novel CSF biomarkers for Alzheimer\u2019s disease and mild cognitive impairment. Acta Neuropathol 119(6):669\u2013678. doi: 10.1007\/s00401-010-0667-0","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2_CR120","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jalz.2014.05.1749","volume":"10","author":"A Hye","year":"2014","unstructured":"Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R et al (2014) Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 10(6):799\u2013807.e2. doi: 10.1016\/j.jalz.2014.05.1749","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2_CR121","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol 2(10):605\u2013613","journal-title":"Lancet Neurol"},{"issue":"1","key":"2_CR122","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tibtech.2010.09.007","volume":"29","author":"C Humpel","year":"2011","unstructured":"Humpel C (2011) Identifying and validating biomarkers for Alzheimer\u2019s disease. Trends Biotechnol 29(1):26\u201332. doi: 10.1016\/j.tibtech.2010.09.007","journal-title":"Trends Biotechnol"},{"issue":"9","key":"2_CR123","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367(9):795\u2013804. doi: 10.1056\/NEJMoa1202753","journal-title":"N Engl J Med"},{"issue":"9","key":"2_CR124","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.biopsych.2013.11.032","volume":"75","author":"O Harari","year":"2014","unstructured":"Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH et al (2014) Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer\u2019s disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry 75(9):723\u2013731. doi: 10.1016\/j.biopsych.2013.11.032","journal-title":"Biol Psychiatry"},{"key":"2_CR125","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/msb.2011.82","volume":"7","author":"M Beck","year":"2011","unstructured":"Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A et al (2011) The quantitative proteome of a human cell line. Mol Syst Biol 7:549. doi: 10.1038\/msb.2011.82","journal-title":"Mol Syst Biol"},{"key":"2_CR126","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/msb.2011.81","volume":"7","author":"N Nagaraj","year":"2011","unstructured":"Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J et al (2011) Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol 7:548. doi: 10.1038\/msb.2011.81","journal-title":"Mol Syst Biol"},{"key":"2_CR127","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainres.2009.01.058","volume":"1265","author":"GN Yin","year":"2009","unstructured":"Yin GN, Lee HW, Cho JY, Suk K (2009) Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 1265:158\u2013170. doi: 10.1016\/j.brainres.2009.01.058","journal-title":"Brain Res"},{"issue":"2","key":"2_CR128","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ana.21038","volume":"61","author":"EJ Finehout","year":"2007","unstructured":"Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer\u2019s disease. Ann Neurol 61(2):120\u2013129. doi: 10.1002\/ana.21038","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"2_CR129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","volume":"118","author":"M Puchades","year":"2003","unstructured":"Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer\u2019s disease. Brain Res Mol Brain Res 118(1\u20132):140\u2013146","journal-title":"Brain Res Mol Brain Res"},{"issue":"12","key":"2_CR130","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1074\/mcp.M500207-MCP200","volume":"4","author":"Y Hu","year":"2005","unstructured":"Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM (2005) Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 4(12):2000\u20132009. doi: 10.1074\/mcp.M500207-MCP200","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"2_CR131","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1471-4159.2009.06158.x","volume":"110","author":"C Zenzmaier","year":"2009","unstructured":"Zenzmaier C, Marksteiner J, Kiefer A, Berger P, Humpel C (2009) Dkk-3 is elevated in CSF and plasma of Alzheimer\u2019s disease patients. J Neurochem 110(2):653\u2013661. doi: 10.1111\/j.1471-4159.2009.06158.x","journal-title":"J Neurochem"},{"issue":"4","key":"2_CR132","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/156720509788929318","volume":"6","author":"CL Maarouf","year":"2009","unstructured":"Maarouf CL, Andacht TM, Kokjohn TA, Castano EM, Sue LI, Beach TG et al (2009) Proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res 6(4):399\u2013406","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"2_CR133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1155\/2005\/806573","volume":"21","author":"EJ Finehout","year":"2005","unstructured":"Finehout EJ, Franck Z, Lee KH (2005) Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21(2):93\u2013101","journal-title":"Dis Markers"},{"issue":"2","key":"2_CR134","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JAD-2005-7205","volume":"7","author":"J Zhang","year":"2005","unstructured":"Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y et al (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7(2):125\u2013133. ;discussion 173-180","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2_CR135","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archneurol.2011.642","volume":"69","author":"JM Ringman","year":"2012","unstructured":"Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F et al (2012) Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 69(1):96\u2013104. doi: 10.1001\/archneurol.2011.642","journal-title":"Arch Neurol"},{"issue":"5","key":"2_CR136","doi-asserted-by":"publisher","first-page":"e64314","DOI":"10.1371\/journal.pone.0064314","volume":"8","author":"RJ Perrin","year":"2013","unstructured":"Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C et al (2013) Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. PLoS One 8(5):e64314. doi: 10.1371\/journal.pone.0064314","journal-title":"PLoS One"},{"issue":"3","key":"2_CR137","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","volume":"9","author":"F Abdi","year":"2006","unstructured":"Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E et al (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9(3):293\u2013348","journal-title":"J Alzheimers Dis"},{"key":"2_CR138","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1326-9-22","volume":"9","author":"KR Wildsmith","year":"2014","unstructured":"Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J et al (2014) Identification of longitudinally dynamic biomarkers in Alzheimer\u2019s disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener 9:22. doi: 10.1186\/1750-1326-9-22","journal-title":"Mol Neurodegener"},{"issue":"8","key":"2_CR139","doi-asserted-by":"publisher","first-page":"e0135365","DOI":"10.1371\/journal.pone.0135365","volume":"10","author":"RC Hendrickson","year":"2015","unstructured":"Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP et al (2015) High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer\u2019s disease in human cerebrospinal fluid. PLoS One 10(8):e0135365. doi: 10.1371\/journal.pone.0135365","journal-title":"PLoS One"},{"issue":"1","key":"2_CR140","doi-asserted-by":"publisher","first-page":"e4183","DOI":"10.1371\/journal.pone.0004183","volume":"4","author":"W Qin","year":"2009","unstructured":"Qin W, Ho L, Wang J, Peskind E, Pasinetti GM (2009) S100A7, a novel Alzheimer\u2019s disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One 4(1):e4183. doi: 10.1371\/journal.pone.0004183","journal-title":"PLoS One"},{"issue":"4","key":"2_CR141","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/rcm.4407","volume":"24","author":"JH Oh","year":"2010","unstructured":"Oh JH, Pan S, Zhang J, Gao J (2010) MSQ: a tool for quantification of proteomics data generated by a liquid chromatography\/matrix-assisted laser desorption\/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. Rapid Commun Mass Spectrom 24(4):403\u2013408. doi: 10.1002\/rcm.4407","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"2","key":"2_CR142","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1179\/016164106X98035","volume":"28","author":"EM Castano","year":"2006","unstructured":"Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer\u2019s disease and non-demented elderly subjects. Neurol Res 28(2):155\u2013163. doi: 10.1179\/016164106X98035","journal-title":"Neurol Res"},{"issue":"2","key":"2_CR143","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/alzrt30","volume":"2","author":"E Portelius","year":"2010","unstructured":"Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E et al (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2(2):7. doi: 10.1186\/alzrt30","journal-title":"Alzheimers Res Ther"},{"issue":"1\u20134","key":"2_CR144","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000334537","volume":"10","author":"E Portelius","year":"2012","unstructured":"Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K (2012) Evaluation of the performance of novel Abeta isoforms as theragnostic markers in Alzheimer\u2019s disease: from the cell to the patient. Neurodegener Dis 10(1\u20134):138\u2013140. doi: 10.1159\/000334537","journal-title":"Neurodegener Dis"},{"issue":"3","key":"2_CR145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1471-4159.2002.00818.x","volume":"81","author":"J Wiltfang","year":"2002","unstructured":"Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S et al (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37\/38\/39 in addition to 1-40\/42 in Alzheimer\u2019s disease and in patients with chronic neuroinflammation. J Neurochem 81(3):481\u2013496","journal-title":"J Neurochem"},{"issue":"5","key":"2_CR146","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1021\/ac102828f","volume":"83","author":"R Verpillot","year":"2011","unstructured":"Verpillot R, Esselmann H, Mohamadi MR, Klafki H, Poirier F, Lehnert S et al (2011) Analysis of amyloid-beta peptides in cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection. Anal Chem 83(5):1696\u20131703. doi: 10.1021\/ac102828f","journal-title":"Anal Chem"},{"issue":"2","key":"2_CR147","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bfgp\/elm010","volume":"6","author":"V Gelfanova","year":"2007","unstructured":"Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER et al (2007) Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic 6(2):149\u2013158. doi: 10.1093\/bfgp\/elm010","journal-title":"Brief Funct Genomic Proteomic"},{"issue":"Pt 5","key":"2_CR148","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/brain\/awl063","volume":"129","author":"M Bibl","year":"2006","unstructured":"Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K et al (2006) CSF amyloid-beta-peptides in Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease dementia. Brain 129(Pt 5):1177\u20131187. doi: 10.1093\/brain\/awl063","journal-title":"Brain"},{"issue":"24","key":"2_CR149","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/rcm.2787","volume":"20","author":"T Oe","year":"2006","unstructured":"Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V et al (2006) Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer\u2019s disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography\/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 20(24):3723\u20133735. doi: 10.1002\/rcm.2787","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"2_CR150","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000100020","volume":"23","author":"AH Simonsen","year":"2007","unstructured":"Simonsen AH, Hansson SF, Ruetschi U, McGuire J, Podust VN, Davies HA et al (2007) Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 23(4):246\u2013250. doi: 10.1159\/000100020","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"2_CR151","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000233353","volume":"28","author":"L Gerhardsson","year":"2009","unstructured":"Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L (2009) Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 28(1):88\u201394. doi: 10.1159\/000233353","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.05.014","author":"J Kuhlmann","year":"2016","unstructured":"Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A et al (2016) CSF Abeta1-42 \u2013 an excellent but complicated Alzheimer\u2019s biomarker \u2013 a route to standardisation. Clin Chim Acta. doi: 10.1016\/j.cca.2016.05.014","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2_CR153","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","volume":"60","author":"A Leinenbach","year":"2014","unstructured":"Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U et al (2014) Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 60(7):987\u2013994. doi: 10.1373\/clinchem.2013.220392","journal-title":"Clin Chem"},{"issue":"2","key":"2_CR154","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-132489","volume":"41","author":"M Korecka","year":"2014","unstructured":"Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M et al (2014) Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 41(2):441\u2013451. doi: 10.3233\/JAD-132489","journal-title":"J Alzheimers Dis"},{"issue":"2\u20133","key":"2_CR155","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000355258","volume":"13","author":"S Tagami","year":"2014","unstructured":"Tagami S, Okochi M, Yanagida K, Kodama T, Arai T, Kuwano R et al (2014) Relative ratio and level of amyloid-beta 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations. Neurodegener Dis 13(2\u20133):166\u2013170. doi: 10.1159\/000355258","journal-title":"Neurodegener Dis"},{"issue":"10","key":"2_CR156","doi-asserted-by":"publisher","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","volume":"6","author":"H Jahn","year":"2011","unstructured":"Jahn H, Wittke S, Zurbig P, Raedler TJ, Arlt S, Kellmann M et al (2011) Peptide fingerprinting of Alzheimer\u2019s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 6(10):e26540. doi: 10.1371\/journal.pone.0026540","journal-title":"PLoS One"},{"issue":"20","key":"2_CR157","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/rcm.7289","volume":"29","author":"S Lehmann","year":"2015","unstructured":"Lehmann S, Vialaret J, Combe GG, Bauchet L, Hanon O, Girard M et al (2015) Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism. Rapid Commun Mass Spectrom 29(20):1917\u20131925. doi: 10.1002\/rcm.7289","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"7","key":"2_CR158","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/pmic.200500285","volume":"6","author":"A Biroccio","year":"2006","unstructured":"Biroccio A, Del Boccio P, Panella M, Bernardini S, Di Ilio C, Gambi D et al (2006) Differential post-translational modifications of transthyretin in Alzheimer\u2019s disease: a study of the cerebral spinal fluid. Proteomics 6(7):2305\u20132313. doi: 10.1002\/pmic.200500285","journal-title":"Proteomics"},{"issue":"8","key":"2_CR159","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/pmic.200300470","volume":"3","author":"O Carrette","year":"2003","unstructured":"Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P et al (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer\u2019s disease. Proteomics 3(8):1486\u20131494. doi: 10.1002\/pmic.200300470","journal-title":"Proteomics"},{"issue":"11","key":"2_CR160","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1002\/jnr.22081","volume":"87","author":"GN Yin","year":"2009","unstructured":"Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K (2009) Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 87(11):2578\u20132590. doi: 10.1002\/jnr.22081","journal-title":"J Neurosci Res"},{"issue":"10","key":"2_CR161","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K et al (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement 11(10):1180\u20131190. doi: 10.1016\/j.jalz.2014.10.009","journal-title":"Alzheimers Dement"},{"key":"2_CR162","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L et al (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener 9:53. doi: 10.1186\/1750-1326-9-53","journal-title":"Mol Neurodegener"},{"issue":"5","key":"2_CR163","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-014-1341-8","volume":"128","author":"M Veitinger","year":"2014","unstructured":"Veitinger M, Oehler R, Umlauf E, Baumgartner R, Schmidt G, Gerner C et al (2014) A platelet protein biochip rapidly detects an Alzheimer\u2019s disease-specific phenotype. Acta Neuropathol 128(5):665\u2013677. doi: 10.1007\/s00401-014-1341-8","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2_CR164","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3233\/JAD-2010-101350","volume":"22","author":"M Thambisetty","year":"2010","unstructured":"Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J et al (2010) Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals. J Alzheimers Dis 22(4):1099\u20131109. doi: 10.3233\/JAD-2010-101350","journal-title":"J Alzheimers Dis"},{"issue":"Pt 11","key":"2_CR165","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/brain\/awl279","volume":"129","author":"A Hye","year":"2006","unstructured":"Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL et al (2006) Proteome-based plasma biomarkers for Alzheimer\u2019s disease. Brain 129(Pt 11):3042\u20133050. doi: 10.1093\/brain\/awl279","journal-title":"Brain"},{"issue":"7","key":"2_CR166","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00702-012-0781-3","volume":"119","author":"AW Henkel","year":"2012","unstructured":"Henkel AW, Muller K, Lewczuk P, Muller T, Marcus K, Kornhuber J et al (2012) Multidimensional plasma protein separation technique for identification of potential Alzheimer\u2019s disease plasma biomarkers: a pilot study. J Neural Transm (Vienna) 119(7):779\u2013788. doi: 10.1007\/s00702-012-0781-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"2_CR167","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1074\/mcp.O115.056986","volume":"15","author":"CE Bakalarski","year":"2016","unstructured":"Bakalarski CE, Kirkpatrick DS (2016) A biologist\u2019s field guide to multiplexed quantitative proteomics. Mol Cell Proteomics 15(5):1489\u20131497. doi: 10.1074\/mcp.O115.056986","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"2_CR168","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3233\/JAD-140111","volume":"41","author":"YH Shih","year":"2014","unstructured":"Shih YH, Tsai KJ, Lee CW, Shiesh SC, Chen WT, Pai MC et al (2014) Apolipoprotein C-III is an amyloid-beta-binding protein and an early marker for Alzheimer\u2019s disease. J Alzheimers Dis 41(3):855\u2013865. doi: 10.3233\/JAD-140111","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2_CR169","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3233\/JAD-141266","volume":"43","author":"J Muenchhoff","year":"2015","unstructured":"Muenchhoff J, Poljak A, Song F, Raftery M, Brodaty H, Duncan M et al (2015) Plasma protein profiling of mild cognitive impairment and Alzheimer\u2019s disease across two independent cohorts. J Alzheimers Dis 43(4):1355\u20131373. doi: 10.3233\/JAD-141266","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2_CR170","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3233\/JAD-2010-100279","volume":"21","author":"A Guntert","year":"2010","unstructured":"Guntert A, Campbell J, Saleem M, O\u2019Brien DP, Thompson AJ, Byers HL et al (2010) Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer\u2019s disease. J Alzheimers Dis 21(2):585\u2013596. doi: 10.3233\/JAD-2010-100279","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2_CR171","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JAD-2010-101722","volume":"24","author":"AD Watt","year":"2011","unstructured":"Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O et al (2011) Increasing the predictive accuracy of amyloid-beta blood-borne biomarkers in Alzheimer\u2019s disease. J Alzheimers Dis 24(1):47\u201359. doi: 10.3233\/JAD-2010-101722","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2_CR172","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JAD-132102","volume":"40","author":"H Yang","year":"2014","unstructured":"Yang H, Lyutvinskiy Y, Herukka SK, Soininen H, Rutishauser D, Zubarev RA (2014) Prognostic polypeptide blood plasma biomarkers of Alzheimer\u2019s disease progression. J Alzheimers Dis 40(3):659\u2013666. doi: 10.3233\/JAD-132102","journal-title":"J Alzheimers Dis"},{"key":"2_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2014.06.024","volume":"840","author":"JS Kim","year":"2014","unstructured":"Kim JS, Ahn HS, Cho SM, Lee JE, Kim Y, Lee C (2014) Detection and quantification of plasma amyloid-beta by selected reaction monitoring mass spectrometry. Anal Chim Acta 840:1\u20139. doi: 10.1016\/j.aca.2014.06.024","journal-title":"Anal Chim Acta"},{"issue":"9","key":"2_CR174","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y et al (2014) Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci 90(9):353\u2013364","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"4","key":"2_CR175","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/WAD.0b013e318239dcbd","volume":"26","author":"S Bennett","year":"2012","unstructured":"Bennett S, Grant M, Creese AJ, Mangialasche F, Cecchetti R, Cooper HJ et al (2012) Plasma levels of complement 4a protein are increased in Alzheimer\u2019s disease. Alzheimer Dis Assoc Disord 26(4):329\u2013334. doi: 10.1097\/WAD.0b013e318239dcbd","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"2_CR176","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3233\/JAD-131088","volume":"38","author":"SL Lundstrom","year":"2014","unstructured":"Lundstrom SL, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka SK, Soininen H et al (2014) Blood plasma IgG Fc glycans are significantly altered in Alzheimer\u2019s disease and progressive mild cognitive impairment. J Alzheimers Dis 38(3):567\u2013579. doi: 10.3233\/JAD-131088","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2_CR177","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/cn5003557","volume":"6","author":"DJ Hare","year":"2015","unstructured":"Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ et al (2015) Decreased plasma iron in Alzheimer\u2019s disease is due to transferrin desaturation. ACS Chem Nerosci 6(3):398\u2013402. doi: 10.1021\/cn5003557","journal-title":"ACS Chem Nerosci"},{"issue":"5","key":"2_CR178","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP et al (2014) Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients and controls. Acta Neuropathol 127(5):633\u2013643. doi: 10.1007\/s00401-014-1266-2","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2_CR179","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/JAD-2011-110731","volume":"27","author":"M Shi","year":"2011","unstructured":"Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I et al (2011) Salivary tau species are potential biomarkers of Alzheimer\u2019s disease. J Alzheimers Dis 27(2):299\u2013305. doi: 10.3233\/JAD-2011-110731","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2_CR180","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00216-012-6261-7","volume":"404","author":"M Bantscheff","year":"2012","unstructured":"Bantscheff M, Kuster B (2012) Quantitative mass spectrometry in proteomics. Anal Bioanal Chem 404(4):937\u2013938. doi: 10.1007\/s00216-012-6261-7","journal-title":"Anal Bioanal Chem"},{"issue":"4","key":"2_CR181","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00216-012-6203-4","volume":"404","author":"M Bantscheff","year":"2012","unstructured":"Bantscheff M, Lemeer S, Savitski MM, Kuster B (2012) Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal Bioanal Chem 404(4):939\u2013965. doi: 10.1007\/s00216-012-6203-4","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"2_CR182","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1586\/14789450.2015.1069188","volume":"12","author":"S Gallien","year":"2015","unstructured":"Gallien S, Domon B (2015) Advances in high-resolution quantitative proteomics: implications for clinical applications. Expert Rev Proteomics 12(5):489\u2013498. doi: 10.1586\/14789450.2015.1069188","journal-title":"Expert Rev Proteomics"},{"issue":"12","key":"2_CR183","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1021\/pr500880b","volume":"13","author":"N Rauniyar","year":"2014","unstructured":"Rauniyar N, Yates JR 3rd (2014) Isobaric labeling-based relative quantification in shotgun proteomics. J Proteome Res 13(12):5293\u20135309. doi: 10.1021\/pr500880b","journal-title":"J Proteome Res"},{"issue":"9\u201310","key":"2_CR184","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/prca.201400149","volume":"9","author":"AR Evans","year":"2015","unstructured":"Evans AR, Gu L, Guerrero R Jr, Robinson RA (2015) Global cPILOT analysis of the APP\/PS-1 mouse liver proteome. Proteomics Clin Appl 9(9\u201310):872\u2013884. doi: 10.1002\/prca.201400149","journal-title":"Proteomics Clin Appl"},{"issue":"22","key":"2_CR185","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/pmic.201300198","volume":"13","author":"AR Evans","year":"2013","unstructured":"Evans AR, Robinson RA (2013) Global combined precursor isotopic labeling and isobaric tagging (cPILOT) approach with selective MS(3) acquisition. Proteomics 13(22):3267\u20133272. doi: 10.1002\/pmic.201300198","journal-title":"Proteomics"},{"issue":"4","key":"2_CR186","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13361-014-1059-9","volume":"26","author":"L Gu","year":"2015","unstructured":"Gu L, Evans AR, Robinson RA (2015) Sample multiplexing with cysteine-selective approaches: cysDML and cPILOT. J Am Soc Mass Spectrom 26(4):615\u2013630. doi: 10.1007\/s13361-014-1059-9","journal-title":"J Am Soc Mass Spectrom"},{"issue":"217","key":"2_CR187","doi-asserted-by":"publisher","first-page":"rs2","DOI":"10.1126\/scisignal.2002548","volume":"5","author":"N Dephoure","year":"2012","unstructured":"Dephoure N, Gygi SP (2012) Hyperplexing: a method for higher-order multiplexed quantitative proteomics provides a map of the dynamic response to rapamycin in yeast. Sci Signal 5(217):rs2. doi: 10.1126\/scisignal.2002548","journal-title":"Sci Signal"},{"key":"2_CR188","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK et al (2015) Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener 10:64. doi: 10.1186\/s13024-015-0059-y","journal-title":"Mol Neurodegener"},{"issue":"6","key":"2_CR189","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","volume":"10","author":"M Sattlecker","year":"2014","unstructured":"Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S et al (2014) Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 10(6):724\u2013734. doi: 10.1016\/j.jalz.2013.09.016","journal-title":"Alzheimers Dement"}],"container-title":["Advances in Experimental Medicine and Biology","Proteomic Methods in Neuropsychiatric Research"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-52479-5_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T04:28:48Z","timestamp":1568953728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-52479-5_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319524788","9783319524795"],"references-count":189,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-52479-5_2","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}